project id: TCGA-PRAD; case submitter id: TCGA-VN-A88O; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.98; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.23; rna integrity number: 7.5; age at index: 49; days to birth: -17945; ethnicity: hispanic or latino; gender: male; race: not reported; vital status: Alive; year of birth: 1963; age at diagnosis: 17945; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 481.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 426; initial weight: 60.0; sample id: 18c49309-d5fc-4ea5-9d5a-5e3cb98b4c4d; sample submitter id: TCGA-VN-A88O-01A; portion id: 008a261e-d7f7-480a-965d-0791cb8f1f62; portion submitter id: TCGA-VN-A88O-01A-11; slide id: c76c5861-67ad-409a-9d67-7065b118119a; slide submitter id: TCGA-VN-A88O-01A-01-TS1; percent lymphocyte infiltration: 60.0; percent monocyte infiltration: 10.0; percent necrosis: 0.0; percent neutrophil infiltration: 20.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 70.0; percent tumor nuclei: 70.0; section location: TOP;